vTv医疗 VTVT 深 沪
等待开盘 09-10 09:30:00 美东时间
18.77
+0.010
+0.05%
华盛通- 最 高20.325
- 今 开20.325
- 成交量 2227股
- 最 低 18.77
- 昨 收 18.76
- 总市值 4912.48万
- 52周最高 26.99
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 12.62
- 委 比 72.41%
- 总股本 261.72万
- 历史最高 560.00
- 量 比 0.30
- 振 幅 8.29%
- 历史最低 7.38
- 每 手 1
- 风险率 5.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多vTv Therapeutics to Participate in Upcoming September Investor Conferences
vTv Therapeutics announced that its management will participate in two September investor conferences: the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, featuring 1x1 investor meetings, and the Morgan Stanley 23rd Annual Global Healthcare Conference on the same day, including a fireside chat from 2:35 PM to 3:10 PM EST and 1x1 investor meetings. The company, focused on developing cadisegliatin for type 1 diabetes,...
09-03 12:00
vTv Therapeutics announces $80M PIPE financing; shares up 14%
vTv Therapeutics (NASDAQ:VTVT) has entered into an $80M private placement in public equity financing. The financing includes participation from existing investors Samsara BioCapital and the T1D Fund, ...
09-02 20:59
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
vTv Therapeutics secures $80 million in private placement financing to support the ongoing Phase 3 CATT1 trial of cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes. The funding will help advance the development of cadisegliatin, which aims to reduce hypoglycemic events and improve glycemic control. The trial's topline data is expected in the second half of 2026. Key investors include Samsara BioCapital, T1D Fun...
09-02 12:00
vTv Therapeutics Q2 EPS $(0.92) Misses $(0.82) Estimate.
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.82) by 11.52 percent. This is a 13.58 percent decrease over losses of $(0.81) per share
08-13 04:17
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
vTv Therapeutics启动cadisegliatin的3期CATT1试验，预计2026年公布结果。其知识产权扩展，领导团队增强。第二季度现金储备降至2590万美元，净亏损600万美元。cadisegliatin作为潜在首创新药，用于治疗1型糖尿病。财务数据显示研发投入增加，净亏损扩大，反映了持续的研发投入。公司致力于缓解糖尿病患者低血糖风险，解决未满足的医疗需求。 ```html vTv Therapeutics启动了cadisegliatin的3期CATT1试验，预计2026年下半年公布结果。公司扩大了知识产权组合，并增强了领导团队。2025年第二季度现金储备为2590万美元，净亏损600万美元。cadisegliatin一种潜在首创新药，可作为胰岛素的辅助疗法用于治疗1型糖尿病。财务数据显示研发投入增加，净亏损扩大。公司致力于通过cadisegliatin缓解糖尿病患者的低血糖风险，解决未满足的医疗需求。 ```
08-12 20:15
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
vTv Therapeutics announced that the USPTO has granted a patent for crystalline forms of salts and co-crystals of cadisegliatin, strengthening its intellectual property protection. The patent, valid until 2041, supports the development of cadisegliatin as a potential first-in-class oral adjunctive therapy for type 1 diabetes. The company highlights its commitment to innovation and regulatory milestones.
08-11 12:00
vTv Therapeutics Announces First Participant Has Been Randomized In Its Phase 3 Catt1 Trial Evaluating Cadisegliatin As An Adjunctive Oral Treatment To Insulin In Adults With Type 1 Diabetes
vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced the first study participant has been
08-07 20:07
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
vTv Therapeutics has initiated its Phase 3 CATT1 trial for cadisegliatin, a potential first-in-class oral treatment for type 1 diabetes (T1D). The drug, which has received FDA Breakthrough Therapy designation, aims to improve glycemic control without increasing hypoglycemia risk. Enrollment is underway at up to 25 U.S. sites, targeting 150 participants treated with insulin. Topline results are expected in late 2026.
08-07 12:00
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
vTv Therapeutics Inc. announced that its management, including CEO Paul Sekhri, CMO Thomas Strack, CSO Carmen Valcarce, and CFO Michael Tung, will participate in H.C. Wainwright’s virtual “HCW@Home” Series on Thursday, June 12, 2025, at 10:00 AM ET. The event will include a fireside chat accessible via a webcast link. vTv is a biopharmaceutical company developing cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes.
06-11 12:00
国内GLP-1创新减重药物研究首登国际顶刊 今年有望与“同门”替尔泊肽在中国市场“同台竞技”
近日，国内GLP-1类创新减重药物玛仕度肽在中国超重或肥胖受试者中的Ⅲ期临床研究（GLORY-1）登上国际知名期刊《新英格兰医学杂志》，这是全球首个且唯一申报上...
05-30 16:41
